Here, we demonstrate that genetic ablation of NLRP3 and antibodies neutralizing circulating IL-1β can effectively prevent atrial remodeling and the development of an AF-promoting substrate, both of which are associated with the development of CKD. This evidence concerns the gene NLRP3 and chronic kidney disease.